SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Hammarström Sten)
 

Search: WFRF:(Hammarström Sten) > Utility of G protei...

  • Ali, HaythamUmeå University,Umeå universitet,Klinisk immunologi,Onkologi,Department of Pathology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt (author)

Utility of G protein-coupled receptor 35 expression for predicting outcome in colon cancer

  • Article/chapterEnglish2019

Publisher, publication year, extent ...

  • 2019-06-28
  • Sage Publications,2019
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:umu-190694
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-190694URI
  • https://doi.org/10.1177/1010428319858885DOI
  • https://lup.lub.lu.se/record/3b8afa0a-0f04-49b1-810c-a44ddf0fea40URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • The utility of mRNA and protein determinations of G protein-coupled receptor 35, that is, GPR35a (GPR35 V1) and GPR35b (GPR35 V2/3), as indicators of outcome for colon cancer patients after curative surgery was investigated. Expression levels of V1 and V2/3 GPR35, carcinoembryonic antigen and CXCL17 mRNAs were assessed in primary tumours and regional lymph nodes of 121 colon cancer patients (stage I–IV), colon cancer cell lines and control colon epithelial cells using real-time quantitative reverse transcriptase-polymerase chain reaction. Expression of G protein-coupled receptor 35 was investigated by two-colour immunohistochemistry and immunomorphometry. GPR35 V2/3 mRNA, but not V1 mRNA, was expressed in colon cancer cell lines, primary colon tumours and control colon epithelial cells. Haematoxylin and eosin positive (H&E(+)), but not H&E(–), lymph nodes expressed high levels of GPR35 V2/3 mRNA (P<0.0001). GPR35b and carcinoembryonic antigen proteins were simultaneously expressed in many colon cancer tumour cells. Kaplan–Meier and hazard ratio analysis revealed that patients with lymph nodes expressing high levels of GPR35 V2/3 mRNA and, in particular, in the group of patients with lymph nodes also expressing carcinoembryonic antigen mRNA, had a short disease-free survival time, 67 months versus 122 months at 12-year follow-up (difference: 55 months, P = 0.001; hazard ratio: 3.6, P = 0.002). In conclusion, high level expression of G protein-coupled receptor 35 V2/3 mRNA in regional lymph nodes of colon cancer patients is a sign of poor prognosis.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • AbdelMageed, ManarUmeå University,Umeå universitet,Klinisk immunologi,Onkologi,Department of Pathology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt(Swepub:umu)maab0124 (author)
  • Olsson, LinaUmeå University,Umeå universitet,Immunologi/immunkemi(Swepub:lu)li7888ol (author)
  • Israelsson, AnneUmeå University,Umeå universitet,Immunologi/immunkemi(Swepub:umu)aneisn00 (author)
  • Lindmark, GudrunLund University,Lunds universitet,Kliniska Vetenskaper, Helsingborg,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUBIN Lab- Lunds laboratorium för neurokirurgisk hjärnskadeforskning,Forskargrupper vid Lunds universitet,Clinical Sciences, Helsingborg,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,LUBIN Lab- Lund Brain Injury laboratory for Neurosurgical research,Lund University Research Groups(Swepub:lu)med-gli (author)
  • Hammarström, Marie-LouiseUmeå University,Umeå universitet,Immunologi/immunkemi(Swepub:umu)maha0008 (author)
  • Hammarström, StenUmeå University,Umeå universitet,Immunologi/immunkemi(Swepub:umu)stha0002 (author)
  • Sitohy, BaselUmeå University,Umeå universitet,Onkologi(Swepub:umu)balsiy01 (author)
  • Umeå universitetKlinisk immunologi (creator_code:org_t)

Related titles

  • In:Tumor Biology: Sage Publications41:61010-42831423-0380

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view